Research report

Efficacy and safety of daratumumab in treatment of relapsed/refractory multiple myeloma

Expand
  • Department of Hematology, the 940th Hospital of Joint Logistics Support Force of Chinese People’s Liberation Army, Gansu 730050, China

Received date: 2022-11-07

  Online published: 2024-01-25

Abstract

Objective To explore the efficacy and safety of daratumumab(DARA) in the treatment of relapsed/refractory multiple myeloma (R/RMM). Methods We retrospectively analyzed 14 patients treated with DARA, who were diagnosed with R/RMM at our hospital during January 2020 to June 2022. The clinical efficacy, progress free survival (PFS), overall response rate (ORR) and safety after treatment were evaluated. Results Total of 14 patients included 8 males and 6 females, in which the median age was 56.5(33-72) years, and the median disease duration was 29.5(10-96) months. The diagnostic classifications were 2 cases of IgA-κ type, 1 case of IgA-λ type, 7 cases of IgG-κ type, 2 cases of IgG-λ type, 2 cases of unsecretory type, respectively. In 14 patients, 5 patients received 2-line therapy in the past, 6 patients received 3-line therapy, and 3 patients received 4-line therapy. All 14 patients completed the first course of DARA treatment and the treatment efficacy was able to be evaluated. Among them, 5 patients achieved hematological complete response (CR), 4 patients achieved very good partial response (VGPR), 2 patients achieved partial response (PR) and 3 patients achieved stable disease(SD). Among them, 13 patients survived, and 1 patient died of lung infection during non-treatment period. The median duration of the disease was 29.5(10-96) months, the median follow-up time was 6(2-14) months, the PFS time was 5(2-12) months, and the ORR was 78.6%. There were no grade Ⅳ adverse reactions during the treatment period. Among them, blood pressure in 1 patient increased and frequent ventricular premature beats occurred in 1 patient. These adverse reactions were both grade Ⅰ adverse reactions., and could be effectively controlled and improved after active treatment. Conclusions R/RMM treated with DARA on the basis of conventional treatment can improve ORR and depth of remission and prolong the PFS of patients, and shows high safety; but its long-term efficacy still needs to be further observed.

Cite this article

ZHOU Rui, WU Tao, XUE Feng, TIAN Hongjuan, LIU Wenhui, MAO Dongfeng . Efficacy and safety of daratumumab in treatment of relapsed/refractory multiple myeloma[J]. Journal of Internal Medicine Concepts & Practice, 2023 , 18(05) : 348 -351 . DOI: 10.16138/j.1673-6087.2023.05.008

References

[1] Rajkumar SV. Multiple myeloma: every year a new standard?[J]. Hematol Oncol, 2019, 37 Suppl 1: 62-65.
[2] Padala SA, Barsouk A, Barsouk A, et al. Epidemiology, staging, and management of multiple myeloma[J]. Med Sci (Basel), 2021, 9(1): 3.
[3] Verhoeven D, Grinwis L, Marsman C, et al. B-cell targeting with anti-CD38 daratumumab: implications for differentiation and memory responses[J]. Life Sci Alliance, 2023, 6(9): e202302214.
[4] Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma(SIRIUS)[J]. Lancet, 2016, 387(10027):1551-1560.
[5] Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma[J]. N Engl J Med, 2019, 380(22): 2104-2115.
[6] Mateos MV, Sonneveld P, Hungria V, et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma[J]. Clin Lymphoma Myeloma Leuk, 2020, 20(8): 509-518.
[7] 蔡真, 陈文明. 复发难治性多发性骨髓瘤治疗解读[J]. 中华内科杂志, 2022, 61(5): 469-473.
[8] 中国医师协会血液科医师分会, 中华医学会血液学分会. 中国多发性骨髓瘤诊治指南(2022年修订)[J]. 中华内科杂志, 2022, 61(5): 480-487.
[9] Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma[J]. Lancet Oncol, 2016, 17(8): e328-e346.
[10] Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0[J]. J Am Acad Dermatol, 2012, 67(5): 1025-1039.
[11] Zavidij O, Haradhvala NJ, Mouhieddine TH, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma[J]. Nat Cancer, 2020, 1(5): 493-506.
[12] Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a glance into future[J]. Haematologica, 2020, 105(10): 2358-2367.
[13] Sperling AS, Anderson KC. Facts and hopes in multiple myeloma immunotherapy[J]. Clin Cancer Res, 2021, 27(16): 4468-4477.
[14] Mateos MV, Hernández MT, Giraldo P, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex)[J]. Lancet Oncol, 2016, 17(8):1127-1136.
[15] Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma[J]. Blood, 2020, 136(8): 936-945.
[16] Zheng Y, Shen H, Xu L, et al. Monoclonal antibodies versus histone deacetylase inhibitors in combination with bortezomib or lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma[J]. J Immunol Res, 2018, 2018: 7646913.
[17] 贾亚静, 刘辉, 王立茹, 等. 达雷妥尤单抗在复发难治性多发性骨髓瘤的应用[J]. 中华内科杂志, 2020, 59(5): 347-348.
[18] Xu W, Li D, Sun Y, et al. Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma[J]. Eur J Haematol, 2019, 103(6): 542-551.
[19] Mateos MV, Spencer A, Nooka AK, et al. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age[J]. Haematologica, 2020, 105(2): 468-477.
[20] Jain A, Ramasamy K. Evolving role of daratumumab: from backbencher to frontline agent[J]. Clin Lymphoma Myeloma Leuk, 2020, 20(9): 572-587.
[21] Htut TW, Quick DP, Win MA, et al. Incidence of second primary malignancies and peripheral sensory neuropathy in patients with multiple myeloma receiving daratumumab containing regimen[J]. Blood, 2019, 134 Suppl 1: 5550.
[22] Voorhees PM, Rodriguez C, Reeves B, et al. Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN[J]. Blood Adv, 2021, 5(4): 1092-1096.
[23] Kiss S, Gede N, Hegyi P, et al. Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes[J]. Sci Rep, 2021, 11(1): 21916.
[24] Garfall AL, Maus MV, Hwang WT, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma[J]. N Engl J Med, 2015, 373(11): 1040-1047.
[25] D’Agostino M, Raje N. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?[J]. Leukemia, 2020, 34(1): 21-34.
[26] 中国医师协会血液科医师分会, 中华医学会血液学分会. 嵌合抗原受体T细胞治疗多发性骨髓瘤中国血液临床专家共识(2022年版)[J]. 中华血液学杂志, 2022, 43(4): 265-271.
Outlines

/